The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $2.21 billion in 2023 to $2.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth observed in the historical period can be attributed to factors such as the increasing aging population, environmental influences, genetic predisposition, restricted treatment options, and advancements in medical technology.
The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $3.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to the continual advancements in targeted therapies, the development of immunotherapies, the adoption of precision medicine approaches, heightened awareness and early detection efforts, and collaborative research initiatives. Significant trends expected in the forecast period encompass a focus on minimal residual disease monitoring, the integration of artificial intelligence (AI) in treatment decision support, an emphasis on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, as well as the implementation of patient advocacy and empowerment programs.
The anticipated growth in the acute myeloid leukemia market is driven by the expanding older population base and increasing unmet healthcare needs. This growth is particularly associated with the elderly population, aged 65 and above, facing health issues such as acute myeloid leukemia. In 2022, the American Cancer Society USA (ACS) reported that AML was prevalent among the elderly, with an average diagnosis age of 68 and notably low survival rates. AML affected around 60,650 individuals in 2022, resulting in 24,000 deaths. Hence, the geriatric population base and the rising healthcare needs contribute to the advancement of the acute myeloid leukemia market.
The growth of the acute myeloid leukemia market is further propelled by the increasing adoption of personalized medicine. This innovative medical approach takes into account individual variations in genes, environments, and lifestyles for treatment and healthcare. In the case of AML, personalized medicine involves molecular profiling to identify specific genetic mutations and biomarkers unique to each patient. This information guides the selection of targeted therapies and customized treatment plans, optimizing intervention effectiveness while minimizing adverse effects. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the rising adoption of personalized medicine is a key driver for the growth of the acute myeloid leukemia market.
A notable trend in the acute myeloid leukemia market is the increasing focus on research and development (R&D) by pharmaceutical groups. R&D efforts aim to develop improved products and services to meet the demands of drug development. For example, a clinical trial titled 'Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)' is in Phase III, initiated in November 2021, and expected to conclude by March 2025, according to the National Library of Medicine.
Major companies in the acute myeloid leukemia market are concentrating on the development of advanced drug solutions, such as maintenance monotherapy, to enhance their product portfolios and address unmet medical needs. Maintenance monotherapy involves administering a single therapeutic agent as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. In July 2023, Daiichi Sankyo Company Limited received approval from the United States Food and Drug Administration (USFDA) for quizartinib (Vanflyta) as maintenance monotherapy for newly diagnosed AML in adults with FLT3 internal tandem duplication (ITD)-positive status. The approval is based on positive results from the QuANTUM-First trial, demonstrating a significant improvement in overall survival. The dosage of quizartinib varies during induction, consolidation, and maintenance phases, and it is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.
In March 2023, QIAGEN partnered with Servier Laboratories for an undisclosed amount to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for AML treatment. This collaboration aims to create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients, using blood and bone marrow samples. The partnership enhances global accessibility to TIBSOVO for AML patients with IDH1 mutations and underscores QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, supporting precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company, is a key player in this collaboration.
Major companies operating in the acute myeloid leukemia market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.
North America was the largest region in the acute myeloid leukemia market in 2023. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatment modalities for acute myeloid leukemia encompass chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy involves the use of potent drugs to eliminate rapidly dividing cells in the body. Various chemotherapeutic agents employed in the treatment of AML include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. These drugs are administered in different regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia treatment is provided by various end-users, including hospitals, retail drug stores, ambulatory care centers, and clinics.
The acute myeloid leukemia market research report is one of a series of new reports that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with an acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $3.21 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to the continual advancements in targeted therapies, the development of immunotherapies, the adoption of precision medicine approaches, heightened awareness and early detection efforts, and collaborative research initiatives. Significant trends expected in the forecast period encompass a focus on minimal residual disease monitoring, the integration of artificial intelligence (AI) in treatment decision support, an emphasis on supportive care and quality of life interventions, collaborative research initiatives and clinical trials, as well as the implementation of patient advocacy and empowerment programs.
The anticipated growth in the acute myeloid leukemia market is driven by the expanding older population base and increasing unmet healthcare needs. This growth is particularly associated with the elderly population, aged 65 and above, facing health issues such as acute myeloid leukemia. In 2022, the American Cancer Society USA (ACS) reported that AML was prevalent among the elderly, with an average diagnosis age of 68 and notably low survival rates. AML affected around 60,650 individuals in 2022, resulting in 24,000 deaths. Hence, the geriatric population base and the rising healthcare needs contribute to the advancement of the acute myeloid leukemia market.
The growth of the acute myeloid leukemia market is further propelled by the increasing adoption of personalized medicine. This innovative medical approach takes into account individual variations in genes, environments, and lifestyles for treatment and healthcare. In the case of AML, personalized medicine involves molecular profiling to identify specific genetic mutations and biomarkers unique to each patient. This information guides the selection of targeted therapies and customized treatment plans, optimizing intervention effectiveness while minimizing adverse effects. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the rising adoption of personalized medicine is a key driver for the growth of the acute myeloid leukemia market.
A notable trend in the acute myeloid leukemia market is the increasing focus on research and development (R&D) by pharmaceutical groups. R&D efforts aim to develop improved products and services to meet the demands of drug development. For example, a clinical trial titled 'Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)' is in Phase III, initiated in November 2021, and expected to conclude by March 2025, according to the National Library of Medicine.
Major companies in the acute myeloid leukemia market are concentrating on the development of advanced drug solutions, such as maintenance monotherapy, to enhance their product portfolios and address unmet medical needs. Maintenance monotherapy involves administering a single therapeutic agent as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. In July 2023, Daiichi Sankyo Company Limited received approval from the United States Food and Drug Administration (USFDA) for quizartinib (Vanflyta) as maintenance monotherapy for newly diagnosed AML in adults with FLT3 internal tandem duplication (ITD)-positive status. The approval is based on positive results from the QuANTUM-First trial, demonstrating a significant improvement in overall survival. The dosage of quizartinib varies during induction, consolidation, and maintenance phases, and it is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.
In March 2023, QIAGEN partnered with Servier Laboratories for an undisclosed amount to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor intended for AML treatment. This collaboration aims to create and validate a real-time in vitro PCR test designed to detect IDH1 gene mutations in AML patients, using blood and bone marrow samples. The partnership enhances global accessibility to TIBSOVO for AML patients with IDH1 mutations and underscores QIAGEN's role in developing companion diagnostics for emerging biomarkers in onco-hematology, supporting precision medicine initiatives. Servier Laboratories, a France-based pharmaceutical company, is a key player in this collaboration.
Major companies operating in the acute myeloid leukemia market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.
North America was the largest region in the acute myeloid leukemia market in 2023. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatment modalities for acute myeloid leukemia encompass chemotherapy, radiation therapy, stem cell transplant, and targeted therapy. Chemotherapy involves the use of potent drugs to eliminate rapidly dividing cells in the body. Various chemotherapeutic agents employed in the treatment of AML include cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, and hormonal therapy. These drugs are administered in different regimens such as DC regimen, AVD regimen, and VCD regimen. Acute myeloid leukemia treatment is provided by various end-users, including hospitals, retail drug stores, ambulatory care centers, and clinics.
The acute myeloid leukemia market research report is one of a series of new reports that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with an acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Acute Myeloid Leukemia Market Characteristics3. Acute Myeloid Leukemia Market Trends and Strategies32. Global Acute Myeloid Leukemia Market Competitive Benchmarking33. Global Acute Myeloid Leukemia Market Competitive Dashboard34. Key Mergers and Acquisitions in the Acute Myeloid Leukemia Market
4. Acute Myeloid Leukemia Market - Macro Economic Scenario
5. Global Acute Myeloid Leukemia Market Size and Growth
6. Acute Myeloid Leukemia Market Segmentation
7. Acute Myeloid Leukemia Market Regional and Country Analysis
8. Asia-Pacific Acute Myeloid Leukemia Market
9. China Acute Myeloid Leukemia Market
10. India Acute Myeloid Leukemia Market
11. Japan Acute Myeloid Leukemia Market
12. Australia Acute Myeloid Leukemia Market
13. Indonesia Acute Myeloid Leukemia Market
14. South Korea Acute Myeloid Leukemia Market
15. Western Europe Acute Myeloid Leukemia Market
16. UK Acute Myeloid Leukemia Market
17. Germany Acute Myeloid Leukemia Market
18. France Acute Myeloid Leukemia Market
19. Italy Acute Myeloid Leukemia Market
20. Spain Acute Myeloid Leukemia Market
21. Eastern Europe Acute Myeloid Leukemia Market
22. Russia Acute Myeloid Leukemia Market
23. North America Acute Myeloid Leukemia Market
24. USA Acute Myeloid Leukemia Market
25. Canada Acute Myeloid Leukemia Market
26. South America Acute Myeloid Leukemia Market
27. Brazil Acute Myeloid Leukemia Market
28. Middle East Acute Myeloid Leukemia Market
29. Africa Acute Myeloid Leukemia Market
30. Acute Myeloid Leukemia Market Competitive Landscape and Company Profiles
31. Acute Myeloid Leukemia Market Other Major and Innovative Companies
35. Acute Myeloid Leukemia Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Acute Myeloid Leukemia Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on acute myeloid leukemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute myeloid leukemia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Treatment Type: Chemotherapy; Radiation therapy; Stem Cell Transplant; Targeted Therapy
2) By Chemotherapy: Cytarabine; Anthracycline Drugs; Alkylating Agents; Anti-metabolites; Tyrosine Kinase Inhibitors; Hormonal Therapy
3) By Regimen: DC Regimen; AVD Regimen; VCD Regimen
4) By End-user: Hospital; Retails Drug Stores; Ambulatory Care Centers; Clinics
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi-Aventis (Genzyme Corporation)
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- AbbVie Inc.
- Novartis AG
- Sanofi-Aventis (Genzyme Corporation)
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Takeda Pharmaceuticals
- Amgen Inc.
- Otsuka Holdings Co. Ltd.
- Teva Pharmaceutical
- Celgene Corporation
- Astellas Pharma
- Servier Pharmaceuticals
- CSPC Pharmaceutical Group
- Genmab AS
- Zhejiang Medicine Co. Ltd.
- Syndax Pharmaceuticals Inc.
- Astex Pharmaceuticals Inc.
- MEI Pharma Inc.
- SELLAS Life Sciences Group
- Ambit Biosciences Corporation
- Agios Pharmaceuticals Inc.
- Neomed Management AS
- Oncolyze Inc.
- TC BioPharm
- VERASTEM INC.
- Mirati Therapeutics Inc.
- Sunshine Lake Pharma
- Sunesis Pharmaceuticals Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 2.39 Billion |
| Forecasted Market Value ( USD | $ 3.21 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
